Jiawei Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiawei Zeng has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Gang Yuan
Department of Geriatrics, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; Department of Private Medical Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2 shared publications Jie Liu
Sun Yat-sen University
2 shared publicationsXiao Chen
Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publications- Yong-Yuan Guan
Department of Pharmacology, Cardiac & Cerebral Vascular Research Center, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 510080, China
2 shared publications - Ai-Min Hui
Global R&D center, Shanghai Fosun Pharmaceutical Development, Co., Ltd, Shanghai, China
1 shared publication Fei-Ya Li
Southern China Agriculture University
1 shared publication
Latest Publications
- Open Access
- 14 October 2025
- Published by SAGE Publications in Sage Open Aging
- Vol. 11
Patterns of Fall Risk-Increasing Drugs and Polypharmacy in Chinese Older Adults Before and After Fall-Related Fractures: A Single Center Retrospective Cohort Study
Background: This study aims to investigate how prescriptions change in hospitals and communities, as well as to assess the impact on the elderly with fall-related fractures. Methods: We retrospectively analyzed data from a single center between 2014 and 2019. The observation outcomes included the number and proportion of all FRIDs and polypharmacy used and divided into 3 cohorts based on FRIDs risk level. Results: In total, 109 patients were included. At admission, 76.1% were used FRIDs and 59.6% were polypharmacy. Six months later, 71.6% continued to use FRIDs and 57.8% were receiving multiple medications. There was no statistically significant difference. The results of the stratified analysis according to risk levels showed a decrease in the number of high-risk FRIDs use during hospital treatment (16.5%) compared to the before hospitalization (31.2%). However, recurrent prescribing occurred in 6 months follow-up periods (29.4%) . Conclusions: There was a high prevalence of FRIDs and polypharmacy in elderly patients following a fall-related fracture. Despite prescription simplification during hospitalization, FRIDs will be utilized again in the community within 6 months. Both physicians and the elderly should pay closer attention to enhance medication management and facilitate appropriate deprescribing in high-risk fall older population.
- 14 October 2025
- Published by SAGE Publications in Sage Open Aging
- Vol. 11
Open AccessPatterns of Fall Risk-Increasing Drugs and Polypharmacy in Chinese Older Adults Before and After Fall-Related Fractures: A Single Center Retrospective Cohort Study
Background: This study aims to investigate how prescriptions change in hospitals and communities, as well as to assess the impact on the elderly with fall-related fractures. Methods: We retrospectively analyzed data from a single center between 2014 and 2019. The observation outcomes included the number and proportion of all FRIDs and polypharmacy used and divided into 3 cohorts based on FRIDs risk level. Results: In total, 109 patients were included. At admission, 76.1% were used FRIDs and 59.6% were polypharmacy. Six months later, 71.6% continued to use FRIDs and 57.8% were receiving multiple medications. There was no statistically significant difference. The results of the stratified analysis according to risk levels showed a decrease in the number of high-risk FRIDs use during hospital treatment (16.5%) compared to the before hospitalization (31.2%). However, recurrent prescribing occurred in 6 months follow-up periods (29.4%) . Conclusions: There was a high prevalence of FRIDs and polypharmacy in elderly patients following a fall-related fracture. Despite prescription simplification during hospitalization, FRIDs will be utilized again in the community within 6 months. Both physicians and the elderly should pay closer attention to enhance medication management and facilitate appropriate deprescribing in high-risk fall older population.
- Open Access
- 6 March 2024
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 2024, 1-10
Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study
Background. Tenapanor is a locally acting selective sodium-hydrogen exchanger 3 inhibitor with the potential to treat sodium/phosphorus and fluid overload in various cardiac-renal diseases, which has been approved for constipation-predominant irritable bowel syndrome in the US. The pharmacokinetics (PK) of tenapanor and its metabolite tenapanor-M1 (AZ13792925), as well as the safety and tolerability of tenapanor, were investigated in healthy Chinese and Caucasian subjects. Methods. This randomized, open-label, single-center, placebo-controlled phase 1 study (https://www.chinadrugtrials.org.cn; CTR20201783) enrolled Chinese and Caucasian healthy volunteers into 4 parallel cohorts (3 cohorts for Chinese subjects, 1 cohort for Caucasian subjects). In each cohort, 15 subjects were expected to be included and received oral tenapanor (10 or 30 mg as single dose, or 50 mg as a single dose followed by a twice-daily repeated dose from Day 5 to 11, with a single dose in the morning on Day 11) or placebo in a 4 : 1 ratio. Results. 59 healthy volunteers received tenapanor 10 mg (n = 12 Chinese), 30 mg (n = 12 Chinese), or 50 mg (n = 12 (Chinese), n = 11 (Caucasian)) or placebo (n = 12, 3 per cohort). After single and twice-daily repeated doses, tenapanor plasma concentrations were all below the limit of quantitation; tenapanor-M1 appeared slowly in plasma. In single-ascending dose evaluation (10 to 50 mg) of Chinese subjects, the mean , AUC0-t, and AUC0-∞ of tenapanor-M1 increased with increasing dose level, and AUC0-t increased approximately dose proportionally. The accumulation ratio was 1.55 to 6.92 after 50 mg repeated dose in Chinese and Caucasian subjects. Exposure to tenapanor-M1 was generally similar between the Chinese and Caucasian subjects. Tenapanor was generally well-tolerated and the safety profile was similar between the Chinese and Caucasian participants receiving tenapanor 50 mg, as measured by vital signs, physical and laboratory examination, 12-lead ECG, and adverse events. No serious adverse event or adverse event leading to withdrawal occurred. Conclusion. Tenapanor was well-tolerated, with similar PK and safety profiles between Chinese and Caucasian subjects. This trial is registered with CTR20201783.- 6 March 2024
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 2024, 1-10
Open AccessPharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study
Background. Tenapanor is a locally acting selective sodium-hydrogen exchanger 3 inhibitor with the potential to treat sodium/phosphorus and fluid overload in various cardiac-renal diseases, which has been approved for constipation-predominant irritable bowel syndrome in the US. The pharmacokinetics (PK) of tenapanor and its metabolite tenapanor-M1 (AZ13792925), as well as the safety and tolerability of tenapanor, were investigated in healthy Chinese and Caucasian subjects. Methods. This randomized, open-label, single-center, placebo-controlled phase 1 study (https://www.chinadrugtrials.org.cn; CTR20201783) enrolled Chinese and Caucasian healthy volunteers into 4 parallel cohorts (3 cohorts for Chinese subjects, 1 cohort for Caucasian subjects). In each cohort, 15 subjects were expected to be included and received oral tenapanor (10 or 30 mg as single dose, or 50 mg as a single dose followed by a twice-daily repeated dose from Day 5 to 11, with a single dose in the morning on Day 11) or placebo in a 4 : 1 ratio. Results. 59 healthy volunteers received tenapanor 10 mg (n = 12 Chinese), 30 mg (n = 12 Chinese), or 50 mg (n = 12 (Chinese), n = 11 (Caucasian)) or placebo (n = 12, 3 per cohort). After single and twice-daily repeated doses, tenapanor plasma concentrations were all below the limit of quantitation; tenapanor-M1 appeared slowly in plasma. In single-ascending dose evaluation (10 to 50 mg) of Chinese subjects, the mean , AUC0-t, and AUC0-∞ of tenapanor-M1 increased with increasing dose level, and AUC0-t increased approximately dose proportionally. The accumulation ratio was 1.55 to 6.92 after 50 mg repeated dose in Chinese and Caucasian subjects. Exposure to tenapanor-M1 was generally similar between the Chinese and Caucasian subjects. Tenapanor was generally well-tolerated and the safety profile was similar between the Chinese and Caucasian participants receiving tenapanor 50 mg, as measured by vital signs, physical and laboratory examination, 12-lead ECG, and adverse events. No serious adverse event or adverse event leading to withdrawal occurred. Conclusion. Tenapanor was well-tolerated, with similar PK and safety profiles between Chinese and Caucasian subjects. This trial is registered with CTR20201783. - 6 February 2021
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 43 (3) , 303-306
Therapeutic Drug Monitoring and Pharmacokinetic Analysis of Cyclosporine in a Pediatric Patient with Hemophagocytic Lymphohistiocytosis Complicated by Diabetes Insipidus: A Grand Round
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease. Initial therapy is based on etoposide, dexamethasone, and cyclosporine (CSA). The pharmacokinetics (PKs) of CSA and other drugs are sometimes altered in patients with HLH complicated by diabetes insipidus (DI) but the precise mechanisms remain unknown. Methods: In this study, the authors present a case of a 4-year-old boy with HLH complicated by DI. CSA concentrations were determined by enzyme multiplied immunoassay technique; noncompartmental PK analysis of the plasma concentration–time data was performed using PKSolver; and linear regression analysis was performed to determine linearity of relationship between urine output and C0 levels of CSA. Results: Although C0 values of CSA were lower than the target levels, the patient was successfully treated and a good clinical outcome was achieved. Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0–24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg. Conclusions: To the best of the authors' knowledge, this is the first report of the CSA PK profile in a patient with HLH complicated by DI. The authors suppose that a large fluid output and input leads to extensive CSA distribution. These results suggest that the monitoring of the Cmax and area under the curve of CSA might be more clinically and pharmacokinetically significant than that of C0 in patients with HLH complicated by DI. This case highlights the importance of therapeutic drug monitoring and demonstrates PK parameters of CSA in a pediatric patient with HLH complicated by DI.
- 6 February 2021
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 43 (3) , 303-306
Therapeutic Drug Monitoring and Pharmacokinetic Analysis of Cyclosporine in a Pediatric Patient with Hemophagocytic Lymphohistiocytosis Complicated by Diabetes Insipidus: A Grand Round
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease. Initial therapy is based on etoposide, dexamethasone, and cyclosporine (CSA). The pharmacokinetics (PKs) of CSA and other drugs are sometimes altered in patients with HLH complicated by diabetes insipidus (DI) but the precise mechanisms remain unknown. Methods: In this study, the authors present a case of a 4-year-old boy with HLH complicated by DI. CSA concentrations were determined by enzyme multiplied immunoassay technique; noncompartmental PK analysis of the plasma concentration–time data was performed using PKSolver; and linear regression analysis was performed to determine linearity of relationship between urine output and C0 levels of CSA. Results: Although C0 values of CSA were lower than the target levels, the patient was successfully treated and a good clinical outcome was achieved. Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0–24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg. Conclusions: To the best of the authors' knowledge, this is the first report of the CSA PK profile in a patient with HLH complicated by DI. The authors suppose that a large fluid output and input leads to extensive CSA distribution. These results suggest that the monitoring of the Cmax and area under the curve of CSA might be more clinically and pharmacokinetically significant than that of C0 in patients with HLH complicated by DI. This case highlights the importance of therapeutic drug monitoring and demonstrates PK parameters of CSA in a pediatric patient with HLH complicated by DI.
- Open Access
- 30 December 2020
- Published by Wiley in Journal of Applied Ichthyology
- Vol. 37 (2) , 227-234
Fin‐spines attachment, a novel external attachment method for the ultrasonic transmitters on hard fin‐spines fish (Sparidae)
- 30 December 2020
- Published by Wiley in Journal of Applied Ichthyology
- Vol. 37 (2) , 227-234
Open AccessFin‐spines attachment, a novel external attachment method for the ultrasonic transmitters on hard fin‐spines fish (Sparidae)
- Open Access
- 1 August 2017
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 61, 23-26
Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia
- 1 August 2017
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 61, 23-26
Open AccessTigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia
- 8 July 2014
- Published by Springer Nature in Apoptosis
- Vol. 19 (9) , 1317-1329
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) prevents apoptosis induced by hydrogen peroxide in basilar artery smooth muscle cells
Cystic fibrosis transmembrane conductance regulator (CFTR) acts as a cAMP-dependent chloride channel, has been studied in various types of cells. CFTR is abundantly expressed in vascular smooth muscle cells and closely linked to vascular tone regulation. However, the functional significance of CFTR in basilar vascular smooth muscle cells (BASMCs) remains elusive. Accumulating evidence has shown the direct role of CFTR in cell apoptosis that contributes to several main pathological events in CF, such as inflammation, lung injury and pancreatic insufficiency. We therefore investigated the role of CFTR in BASMC apoptotic process induced by hydrogen peroxide (H2O2). We found that H2O2-induced cell apoptosis was parallel to a significant decrease in endogenous CFTR protein expression. Silencing CFTR with adenovirus-mediated CFTR specific siRNA further enhanced H2O2-induced BASMC injury, mitochondrial cytochrome c release into cytoplasm, cleaved caspase-3 and -9 protein expression and oxidized glutathione levels; while decreased cell viability, the Bcl-2/Bax ratio, mitochondrial membrane potential, total glutathione levels, activities of superoxide dismutase and catalase. The pharmacological activation of CFTR with forskolin produced the opposite effects. These results strongly suggest that CFTR may modulate oxidative stress-related BASMC apoptosis through the cAMP- and mitochondria-dependent pathway and regulating endogenous antioxidant defense system.
- 8 July 2014
- Published by Springer Nature in Apoptosis
- Vol. 19 (9) , 1317-1329
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) prevents apoptosis induced by hydrogen peroxide in basilar artery smooth muscle cells
Cystic fibrosis transmembrane conductance regulator (CFTR) acts as a cAMP-dependent chloride channel, has been studied in various types of cells. CFTR is abundantly expressed in vascular smooth muscle cells and closely linked to vascular tone regulation. However, the functional significance of CFTR in basilar vascular smooth muscle cells (BASMCs) remains elusive. Accumulating evidence has shown the direct role of CFTR in cell apoptosis that contributes to several main pathological events in CF, such as inflammation, lung injury and pancreatic insufficiency. We therefore investigated the role of CFTR in BASMC apoptotic process induced by hydrogen peroxide (H2O2). We found that H2O2-induced cell apoptosis was parallel to a significant decrease in endogenous CFTR protein expression. Silencing CFTR with adenovirus-mediated CFTR specific siRNA further enhanced H2O2-induced BASMC injury, mitochondrial cytochrome c release into cytoplasm, cleaved caspase-3 and -9 protein expression and oxidized glutathione levels; while decreased cell viability, the Bcl-2/Bax ratio, mitochondrial membrane potential, total glutathione levels, activities of superoxide dismutase and catalase. The pharmacological activation of CFTR with forskolin produced the opposite effects. These results strongly suggest that CFTR may modulate oxidative stress-related BASMC apoptosis through the cAMP- and mitochondria-dependent pathway and regulating endogenous antioxidant defense system.
- 10 June 2014
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (13) , 3158-3170
Integrin β3 mediates cerebrovascular remodelling through Src/ClC‐3 volume‐regulated Cl− channel signalling pathway
Background and Purpose: Cerebrovascular remodelling is one of the important risk factors of stroke. The underlying mechanisms are unclear. Integrin β3 and volume‐regulated ClC‐3 Cl− channels have recently been implicated as important contributors to vascular cell proliferation. Therefore, we investigated the role of integrin β3 in cerebrovascular remodelling and related Cl− signalling pathway.Experimental Approach: Cl− currents were recorded using a patch clamp technique. The expression of integrin β3 in hypertensive animals was examined by Western blot and immunohistochemisty. Immunoprecipitation, cDNA and siRNA transfection were employed to investigate the integrin β3/Src/ClC‐3 signalling.Key Results: Integrin β3 expression was up‐regulated in stroke‐prone spontaneously hypertensive rats, 2‐kidney 2‐clip hypertensive rats and angiotensin II‐infused hypertensive mice. Integrin β3 expression was positively correlated with medial cross‐sectional area and ClC‐3 expression in the basilar artery of 2‐kidney 2‐clip hypertensive rats. Knockdown of integrin β3 inhibited the proliferation of rat basilar vascular smooth muscle cells induced by angiotensin II. Co‐immunoprecipitation and immunofluorescence experiments revealed a physical interaction between integrin β3, Src and ClC‐3 protein. The integrin β3/Src/ClC‐3 signalling pathway was shown to be involved in the activation of volume‐regulated chloride channels induced by both hypo‐osmotic stress and angiotensin II. Tyrosine 284 within a concensus Src phosphorylation site was the key point for ClC‐3 channel activation. ClC‐3 knockout significantly attenuated angiotensin II‐induced cerebrovascular remodelling.Conclusions and Implications: Integrin β3 mediates cerebrovascular remodelling during hypertension via Src/ClC‐3 signalling pathway.
- 10 June 2014
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (13) , 3158-3170
Integrin β3 mediates cerebrovascular remodelling through Src/ClC‐3 volume‐regulated Cl− channel signalling pathway
Background and Purpose: Cerebrovascular remodelling is one of the important risk factors of stroke. The underlying mechanisms are unclear. Integrin β3 and volume‐regulated ClC‐3 Cl− channels have recently been implicated as important contributors to vascular cell proliferation. Therefore, we investigated the role of integrin β3 in cerebrovascular remodelling and related Cl− signalling pathway.Experimental Approach: Cl− currents were recorded using a patch clamp technique. The expression of integrin β3 in hypertensive animals was examined by Western blot and immunohistochemisty. Immunoprecipitation, cDNA and siRNA transfection were employed to investigate the integrin β3/Src/ClC‐3 signalling.Key Results: Integrin β3 expression was up‐regulated in stroke‐prone spontaneously hypertensive rats, 2‐kidney 2‐clip hypertensive rats and angiotensin II‐infused hypertensive mice. Integrin β3 expression was positively correlated with medial cross‐sectional area and ClC‐3 expression in the basilar artery of 2‐kidney 2‐clip hypertensive rats. Knockdown of integrin β3 inhibited the proliferation of rat basilar vascular smooth muscle cells induced by angiotensin II. Co‐immunoprecipitation and immunofluorescence experiments revealed a physical interaction between integrin β3, Src and ClC‐3 protein. The integrin β3/Src/ClC‐3 signalling pathway was shown to be involved in the activation of volume‐regulated chloride channels induced by both hypo‐osmotic stress and angiotensin II. Tyrosine 284 within a concensus Src phosphorylation site was the key point for ClC‐3 channel activation. ClC‐3 knockout significantly attenuated angiotensin II‐induced cerebrovascular remodelling.Conclusions and Implications: Integrin β3 mediates cerebrovascular remodelling during hypertension via Src/ClC‐3 signalling pathway.